ABVC BioPharma, Inc. (ABVC)

Compare

1.3200

+0.2600

+(24.53%)

At close: April 1 at 4:00:01 PM EDT

1.3200

0.00

(0.00%)

After hours: April 1 at 7:58:06 PM EDT

ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential

Expecting $19 Million Cash Income FREMONT, CA - March 19, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncol...

NewMediaWire 13 days ago

ABVC
+24.53%
ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs

Over $100 Million Invested in the U.S. FREMONT, CA - March 5, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and ...

NewMediaWire 27 days ago

ABVC
+24.53%
ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets

FREMONT, CA - February 26, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, announces a new...

NewMediaWire last month

ABVC
+24.53%
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025

FREEMONT, CALIFORNIA - February 20, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, central nervous system (CNS), and oncology/hematology, today ...

NewMediaWire last month

ABVC
+24.53%
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion

FREMONT, CA - February 12, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focusing on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announce...

NewMediaWire last month

ABVC
+24.53%
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Focusing on Neuroscience, Oncology, and Ophthalmology Pipelines FREMONT, CA - January 16, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (ce...

NewMediaWire 2 months ago

ABVC
+24.53%
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market

FREMONT, CA - January 15, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is proud to anno...

NewMediaWire 2 months ago

ABVC
+24.53%
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees

Licensing Fees From AiBtl and Strategic Partners Now Total $696,000, Bolstering Confidence in AiBtl's Plans FREMONT, CA - January 14, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on inn...

NewMediaWire 2 months ago

ABVC
+24.53%
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement

FREMONT, CA - January 13, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is pleased to an...

NewMediaWire 2 months ago

ABVC
+24.53%
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products

Revolutionary Patented Technology Poised to Address Unmet Medical Needs in a Transformative $4.3 Billion Market Opportunity FREMONT, CA - January 7, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical compan...

NewMediaWire 2 months ago

ABVC
+24.53%
ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market

FREMONT, CA - (NewMediaWire) - January 2, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in ophthalmology, neurology, and oncology/hematology, is announcing the approval of its patent application b...

NewMediaWire 2 months ago

ABVC
+24.53%
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

FREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced in response to the discontinuation of Prozac[1] due to increasing concerns around side effects, ABVC believes its ABV-1504, which has the API, “Radix Polygala”, known as Polygala tenuifolia Willd or PDC-1421, can fill this void in the mental healt

GlobeNewswire 3 months ago

ABVC
+24.53%
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. ("OncoX") as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX.

GlobeNewswire 3 months ago

ABVC
+24.53%
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in incomeReceived Cash Milestone Incomes of $496,000 for the nine months ended September 30, 2024 FREMONT, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncolog

GlobeNewswire 4 months ago

ABVC
+24.53%
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has recei

GlobeNewswire 5 months ago

ABVC
+24.53%
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational

GlobeNewswire 7 months ago

ABVC
+24.53%
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI

FREMONT, CA - (NewMediaWire) - July 9, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that afte...

NewMediaWire 8 months ago

ABVC
+24.53%
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals

FREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, anno...

NewMediaWire 8 months ago

ABVC
+24.53%
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market

The Company holds a U.S. patent for the same treatmentFREMONT, CA - (NewMediaWire) - June 25, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurol...

NewMediaWire 9 months ago

ABVC
+24.53%
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue

FREMONT, CA - (NewMediaWire) - June 12, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, ann...

NewMediaWire 9 months ago

ABVC
+24.53%

Performance Overview

Return	ABVC	S&P 500 (^GSPC)
YTD	+123.73%	-4.23%
1-Year	-3.65%	+7.42%
3-Year	-95.13%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ABVC BioPharma, Inc. (ABVC)

ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential

ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs

ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets

ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025

Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion

ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference

ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market

AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees

ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement

ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products

ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI

ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals

ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market

ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue

Performance Overview